As Chief Executive Officer of Diaceutics Group, and Chairman of Labceutics, Peter Keeling has led creation of a highly data enabled personalised medicine integrator focused largely on the needs of the pharmaceutical companies to embed biomarkers and tests into their business model. . Peter recognized early on that personalized medicine would be an increasingly large part of the drug development paradigm, representing a paradigm shift in how the pharmaceutical industry operates.Today Diaceutics Group is both a thought leader in the space and provides the top 20 PM Pharma companies with the data, analytics and global Lab implementation services required to align biomarker and diagnostic demand with therapy patient and revenue targets in key markets. .

Peter brings over thirty  years of experience in international healthcare first at GSK and Diagnology and then at Diaceutics. He has operated and led companies  and teams in the US, Europe, Asia and BRIC counties. Across these organisations Peter has inspired product innovation and global launches and repeatedly delivered high corporate value growth for shareholders.

Peter has spent two extended periods in applied industrial research, including a year at MIT’s Pharmaceutical Program at the Sloan School of Management in Boston, has published widely and is considered a thought leader in Personalized Medicine commercialisation.